

Hoxb7 Inhibits Transgenic HER-2/neu-Induced Mouse Mammary Tumor Onset but Promotes Progression and Lung Metastasis

Hexin Chen,¹ Ji Shin Lee,¹ Xiaohui Liang,¹ Huiping Zhang,¹ Tao Zhu,¹ Zhe Zhang,¹ M. Evangeline Taylor,¹ Cynthia Zahnow,¹ Lionel Feigenbaum,² Alan Rein,³ and Saraswati Sukumar¹

¹The Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland and ²Laboratory Animal Science Program, Science Applications International Corporation; and ³HIV Drug Resistance Program, National Cancer Institute-Frederick, Frederick, Maryland

Abstract

Our previous studies have shown that *HOXB7* mRNA is overexpressed in ~50% of invasive breast carcinomas and promotes tumor progression in breast cancer cells grown as xenografts in mice. *In silico* analysis of published microarray data showed that high levels of *HOXB7* predict a poor outcome in HER-2-positive ($P = 0.046$), but not in HER-2-negative breast cancers ($P = 0.94$). To study the function of *HOXB7* *in vivo* in the context of HER-2 overexpression, we generated mouse mammary tumor virus (*MMTV*)-*Hoxb7* transgenic mice, and then crossed them with *MMTV-HER-2/neu* transgenic mice. In the mice carrying both *Hoxb7* and *HER-2/neu* transgenes, *Hoxb7* plays a dual role in mammary tumorigenesis. In double transgenic mice, overexpression of *Hoxb7* delayed tumor onset and lowered tumor multiplicity. However, consistent with the clinical data, once the tumors appeared, their growth was faster and metastasis to the lungs occurred at a higher frequency. Our data show, for the first time, that deregulated expression of *Hoxb7* in mammary tumor cells can significantly modulate *HER-2/neu*-oncogene induced tumorigenesis *in vivo*. [Cancer Res 2008;68(10):3637–44]

Introduction

HOX genes were initially discovered in *Drosophila* where they control segment identity through regulating cellular proliferation, differentiation, and death (1). In humans, there are at least 39 *HOX* genes, organized in four clusters (A, B, C, and D) located on chromosomes 7, 17, 2, and 12, respectively (1). A potential role for *HOX* genes in neoplasia was first documented in leukemia (2). Since then, alterations in *HOX* gene expression have been detected in a variety of human tumors and derivative cell lines (3–5). Although many *in vitro* cell culture and xenograft injection studies have shown that deregulated *HOX* genes can promote cellular transformation and tumor progression, thus far, no evidence has been presented that their gain or loss of function can directly cause tumor formation *in vivo* (6, 7).

In recent years, a small number of studies have suggested that *HOXB7*, a member of the *HOX* gene family, plays a role in tumorigenesis. First, frequent overexpression of *HOXB7* was reported in

melanoma, ovarian, and breast cancer cell lines, as well as primary tumors (8, 9). Secondly, overexpression of *HOXB7* in the breast cancer cell line SKBR3 increased proliferation and angiogenesis by up-regulating basic fibroblast growth factor (bFGF; refs. 8, 10, 11). Recently, our data has shown that overexpression of *HOXB7* in breast cancer cells induced epithelial-mesenchymal transition (12), a critical step for metastasis. These results pointed to a potential oncogenic role for *HOXB7* in breast cancer.

To investigate the role of *HOXB7* in breast tumorigenesis *in vivo*, we generated a mouse mammary tumor virus (*MMTV*)-*Hoxb7* FVB/N transgenic mouse model where expression of *Hoxb7* is regulated by the *MMTV* promoter. Our preliminary data showed that overexpression of *Hoxb7* alone in this strain of mouse was insufficient to induce tumor formation. To test whether overexpression of *Hoxb7* potentiates tumorigenesis induced by other oncogenes, we crossed the *MMTV-Hoxb7* with *MMTV-HER-2/neu* transgenic mice, which are known to develop mammary tumors at 6 to 12 months of age. Interestingly, we found that overexpressed *Hoxb7* in the mammary gland played a dual role in *HER-2/neu*-induced tumorigenesis: it delayed tumor onset but promoted metastatic tumor progression.

Materials and Methods

***In silico* microarray data analysis.** The clinical effect of the gene expression profiles of *HOXB7* was evaluated using a published data set of breast cancer patients (13). This data set includes 286 lymph node-negative breast cancer patients who received no adjuvant treatment. The mean expression value was used as the cutoff to classify *HOXB7* expression as high or low. Recurrence-free survival was estimated using the Kaplan-Meier method and compared with log-rank tests. The *HER-2* expression status was statistically classified as described previously (14). All statistical tests were two-sided, and differences were considered statistically significant at $P < 0.05$. All analyses were performed using SAS (version 9.1) and R (version 2.4.1).

Generation and identification of transgenic mice. The full-length mouse *Hoxb7* cDNA was amplified by PCR and inserted into a pMMTV vector (a kind gift from Dr. Jeffrey Rosen at Baylor College of Medicine)⁴ to generate the plasmid pMMTV-*Hoxb7*. Microinjections were performed by the Transgenic Mouse Core Facility at National Cancer Institute. Transgenic progeny were identified by Southern blot analysis, and PCR using genomic DNA was isolated from a tail biopsy. In brief, the tip of the tail was cut from 4-week-old mice. The tail DNA was extracted by digesting with proteinase K in 300 μ L of lysis buffer overnight, followed by heating at 95°C for 10 min to inactivate the enzyme. After centrifugation, 1 μ L of the supernatant was used for PCR reaction. The two pairs of primers used to detect the intact

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Requests for reprints: Saraswati Sukumar, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB-I Room 143, Baltimore, MD 21231-1000. Phone: 410-614-2479; Fax: 410-614-4073; E-mail: saras@jhmi.edu.

©2008 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-2926

⁴ <http://www.bcm.edu/rosenlab/vectors.html>

Hoxb7 gene were KCRI (5'-TTC TGG CTG GCG TGG AAA TA-3') and Hoxb7.2 (5'-GAA GCA AAG GCG CAA GAA GT-3') for detection of the 5' end sequence of *Hoxb7* gene, and polyA3 (5'-CCC AGA ATA GAA TGA CAC CT-3') and Hoxb7.7 (5'-ACA GAT CAA GAT CTG GTT TC-3') for detection of the 3' end sequence.

Mouse breeding. The mice were housed and treated in accordance with NIH Guide to Humane Use of Animals in Research. All surgical procedures were approved by the Johns Hopkins University Animal Care and Use Committee. The MMTV-*HER-2/neu* mice are purchased from The Jackson Laboratory. Both MMTV-*Hoxb7* and MMTV-*HER-2/neu* mice were on the FVB background. The hemizygous MMTV-*Hoxb7* and MMTV-*HER-2/neu* mice were intercrossed to generate progeny of following genotypes: wild type (wt), MMTV-*neu*, MMTV-*Hoxb7*, and MMTV-*Hoxb7/MMTV-*neu**. Age-matched virgin mice were used for phenotypic and genotypic alterations.

Whole mount staining analysis of mammary gland. Mammary glands were stained as previously described (15). Inguinal mammary fat pads were excised from euthanized mice and stretched on a histologic glass slide. The fat pads were placed in 10% formalin for at least 24 h and then defatted in acetone for 2 d. The fat pads were rehydrated in a graded series of alcohols to distilled water and stained with hematoxylin for 4 to 6 h. The stained slides were washed in tap water and then dehydrated in a graded series of alcohols and transferred to xylene, and coverslips were mounted with Permount mounting media (Fisher Scientific). Five mice per genotype were analyzed.

Reverse transcription-PCR analysis. Reverse transcription-PCR was performed as described previously for the genes queried using primers Hoxb7F2 (5'-ACC GAG TTC CTT CAA CAT GC-3') and Hoxb7R2 (5'-CCG AGT CAG GTA GCG ATT GT-3'; ref. 16).

Western blot analysis. Western blot analysis was done using standard procedure (16). *HER-2/neu* antibody was purchased from Santa Cruz Biotechnology, Inc.

Histologic assay. Mammary tumor formation was monitored in nulliparous mice by weekly physical palpation. Mammary tumors and lung tissue were harvested from mice bearing tumors for 70 d. Histologic services were provided by the Department of Pathology at the Johns Hopkins School of Medicine.

Tumors were graded according to the modified Elston and Ellis histologic grading system (17). In brief, three tumor characteristics were evaluated: tubule formation, nuclear pleomorphism, and mitotic counts. A numerical scoring system of 1 to 3 was used to ensure that each factor was assessed individually. The three values were added together to produce scores of 3 to 9, to which the grade was assigned as follows: grade 1, well differentiated (3–5 points); grade 2, moderately differentiated (6–7 points); and grade 3, poorly differentiated (8–9 points). Mitotic cells were counted in random 10 high-power fields ($\times 400$) for each tumor sample. Lung metastases identified by microscopic analysis were called "micrometastasis," and the total number of foci in a section of the entire lung was counted.

Assessment of angiogenesis, proliferation, and apoptosis. Immunohistochemical analysis was performed as previously described (18). Angiogenesis, proliferation, and apoptotic index were assessed by immunohistochemical staining analysis of primary tumors using antibody against CD34 (Dako), active caspase-3 (BD Sciences), and Ki67 (BD PharMingen), respectively. Angiogenesis was evaluated by investigators blinded to the identity of the mice by counting blood vessels in three areas of the section at $200\times$ magnification. Microvessel counts were expressed as the mean number of vessels in the three areas. To assess proliferation and apoptotic rate, 1,000 tumor cells were counted, and the percentage of positive staining cells is presented in the figures.

Results

The expression status of *HOXB7* predicts clinical outcome in *HER-2*-positive breast cancer. Our previous data showed that *HOXB7* was overexpressed in the majority of invasive breast carcinomas (12). To test whether overexpression of *HOXB7* has

clinical consequences in breast cancer, we performed statistical analyses *in silico* using published microarray data on 286 lymph node-negative breast cancers (13). Absence of any therapy, pre-surgery or postsurgery, permitted the evaluation of the prognostic role of the marker, without the confounding effects of therapy (13). In this cohort, *HOXB7* expression alone did not significantly predict clinical outcome. However, when the patients were divided into *HER-2*-positive ($n = 72$) and *HER-2*-negative ($n = 214$) subgroups, we found that the expression status of *HOXB7* was a strong prognostic biomarker for development of metastasis in the *HER-2*-positive subgroup ($P = 0.046$). High *HOXB7* expression in 27 of 72 *HER-2*-positive cancers (37%) was significantly associated with decreased distant metastasis-free survival ($P = 0.046$). Compared with *HER-2*-positive patients with low *HOXB7* expression ($n = 54$) or *HER-2*-negative patients ($n = 214$), the *HER-2*-positive patients with high *HOXB7* expression displayed the worst clinical outcome. The *HER-2*-negative group of patients showed very similar metastasis-free survival rate regardless of *HOXB7* expression status ($P = 0.94$; Fig. 1). Seventy-four of 214 *HER-2*-negative tumors (35%) expressed high levels of *HOXB7*, which was very similar to the percentage of *HER-2*-positive tumors with high *HOXB7* expression (37%). Thus, in all likelihood, *HOXB7* expression is not associated with the expression status of *HER-2*. These data suggested that *HOXB7* can serve as an independent prognostic marker to




Figure 1. Expression status of *HOXB7* predicts clinical outcome. The 286 lymph node-negative breast cancer patients were divided into three subgroups based on their *HER-2* expression status: All ($n = 286$), *HER-2+* ($n = 72$), and *HER-2-* ($n = 214$) groups. The mean expression value was used to set the cutoff that classified *HOXB7* expression as high or low. *HER-2*-positive patients ($n = 72$), 27 patients with high *HOXB7* expression versus 45 patients with low *HOXB7* expression; *HER-2*-negative group ($n = 214$), 74 patients with high *HOXB7* expression versus 140 patients with low *HOXB7* expression. The Y axis represents the probability of metastasis-free survival.

identify a subgroup of HER-2-positive patients with worse clinical outcome. Furthermore, it raised the possibility that HOXB7 may have the potential to modulate HER-2-induced mammary tumorigenesis.

Overexpression of Hoxb7 impairs HER-2/neu-induced mammary tumor onset. To study the role of Hoxb7 in mammary tumorigenesis *in vivo*, we generated an *MMTV-Hoxb7* transgenic mouse model (Supplementary Figs. S1–S3). Overexpression of *Hoxb7* alone was insufficient to form tumors in the *MMTV-Hoxb7* transgenic mice during the 2 years of observation. Because our clinical data analysis suggested that overexpression of HOXB7 may render tumors aggressive and promote metastatic features in HER-2/neu-positive breast cancer, we crossed the *MMTV-Hoxb7* transgenic mice with *MMTV-HER-2/neu* transgenic mice carrying the wt rat HER-2/neu gene. *MMTV-HER-2/neu* transgenic mice develop mammary carcinomas and lung metastasis stochastically with a long latency (19), suggesting that overexpression of wt HER-2/neu alone is not sufficient to initiate tumorigenesis and another genetic or epigenetic event is required for HER-2/neu-mediated tumorigenesis. We theorized that overexpression of Hoxb7 and HER-2/neu in mammary epithelial cells could result in an acceleration of tumorigenesis and an increase in metastatic progression due to cooperation of the two oncogenes, or alternatively, in an inhibition of tumorigenesis due to premature senescence and differentiation (20, 21).

Interestingly, we found that overexpression of Hoxb7 significantly inhibited tumor onset and delayed the latency by ~6 months (231 days versus 406 days; Fig. 2A). A similar phenotype was observed in two other *Hoxb7* transgenic lines when crossed with *MMTV-HER-2/neu* transgenic mice (Supplementary Fig. S4). These data suggested that overexpression of Hoxb7 exerted a repressive effect on tumor initiation by the *HER-2/neu* oncogene. Consistent with this observation, upon sacrificing mice at 10 weeks after first palpation of the tumor, we found significantly reduced tumor multiplicity (2.6 ± 0.2 versus 1.5 ± 0.1 tumors per mouse; $P = 0.0002$) in mice overexpressing both Hoxb7 and HER-2/neu, compared with those expressing the single HER-2/neu transgene (Fig. 2B and C).

Overexpression of Hoxb7 modulates mammary gland development and rescues MMTV-HER-2/neu-caused defects in ductal elongation. It is possible that the inhibition of tumor onset is attributable to defects in mammary gland development in mice carrying both transgenes. Most steps of mouse mammary gland maturation occur postnatally. This provides an excellent system to study the function of oncogenes during mammary gland development and during tumorigenesis, which occurs as a consequence of a derailed developmental program. Normally, the epithelial ductal tree begins to grow rapidly at around 3 weeks of age upon the release of ovarian hormones. This rapid growth is inhibited when ducts approach the edge of the fat pad at around 10 to 12 weeks of age. During pregnancy, the hormones, progesterone, and prolactin, stimulate secondary branching and formation of lobular alveolar structures in preparation for the production of milk for suckling pups upon parturition. Beginning at day 3 postweaning, involution occurs and milk-producing epithelial cells die through apoptosis (15). To examine the effects of *Hoxb7* and *neu* overexpression in mammary gland development, we performed whole-mount staining analysis in the mammary glands of transgenic mice at different stages of mammary gland development (virgin mice at 8 and 13 weeks old; pregnancy day 10 and involution day 3).




Figure 2. Overexpression of Hoxb7 inhibits HER-2/neu-induced tumor onset. *A*, kinetics of tumor formation in the *HER-2/neu* and *Hoxb7/HER-2/neu* transgenic mice. The number of tumor-free days for each group of animals is shown. T_{50} represents the time point when 50% of mice in that group developed tumors. *B*, tumors harvested from two representative *HER-2/neu* and *Hoxb7/HER-2/neu* transgenic mice showing both size and multiplicity 10 wk after first detection of a palpable mass. *C*, mammary tumor multiplicity was significantly different ($P = 0.0002$) in the *HER-2/neu* versus *Hoxb7xHER-2/neu* mice.

At 8 weeks, the ductal tree in the wt mouse mammary gland filled the fat pad almost completely. The mouse ductal tree of the *Hoxb7* transgenic mouse seemed very similar to that in the wt mouse, except that there was a slightly greater level of branching. In the *HER-2/neu* transgenic mouse, ductal tree development was inhibited, confirming published findings (22, 23). The ductal tree extended only up to the lymph node, which is located in the center of mammary gland. Interestingly enough, in the double transgenic mice, the phenotype in *HER-2/neu* transgenic mice was partially rescued by Hoxb7, in that the mammary glands in the double transgenic mice grew beyond the lymph node, appearing more like the wt gland. At 13 weeks, very similar phenotypes were observed between wt, *HER-2/neu*, *Hoxb7*, and dual transgenic mice. Again, overexpression of Hoxb7 increased side branching and completely rescued the *HER-2/neu* phenotype (Fig. 3A and B). During pregnancy, there were no significant phenotypic differences in the mammary gland among these mice. At the involution stage, overexpression of Hoxb7 dramatically accelerated the involution process (Fig. 3A and C). At involution day 3, the alveolar structure was still intact in the wt mammary gland and some of epithelial cells begin to mobilize into the luminal spaces of alveoli. On the other hand, in the mammary gland of *MMTV-Hoxb7* transgenic

mice, most of the alveolar structures had already collapsed into clusters of epithelial cells and more adipocytes seem to be refilling the spaces. *HER-2/neu* is known to delay this process (24). As seen in Fig. 3C, at this time point, the alveolar structures in the *HER-2/neu* mice were largely intact and filled with milk. The phenotype of the mammary gland of the double transgenic mice was very similar to that in the wt mice. In a nutshell, *Hoxb7* and *HER-2/neu* seemed to play opposing roles in mammary gland development. These data are consistent with our finding that *Hoxb7* delayed *HER-2/neu*-induced mammary tumor onset.

The apparent opposing effects of *Hoxb7* and *HER-2/neu* on mammary gland development prompted us to examine whether *Hoxb7* directly down-regulates the expression level of *neu* in mammary epithelium. Immunohistochemical analysis and Western blot analysis confirmed that the expression level of *neu* was not reduced in the mammary epithelium and tumor cells from double transgenic mouse. On the contrary, the expression level of *neu* was slightly higher in some of tumor cell lines derived from the double transgenic mouse tumors (data not shown and Supplementary Fig. S5). As expected, *Hoxb7* expression was detected only in the

MMTV-Hoxb7 × *MMTV-HER-2/neu* transgenic mammary tumor cells (Supplementary Fig. S6). Thus, the inhibition of tumor onset in the *MMTV-Hoxb7* × *MMTV-HER-2/neu* mice was not caused by suppression of expression of the *neu* oncogene.

Overexpression of *Hoxb7* promotes tumor progression and pulmonary metastasis. Despite the delay in tumor onset in double transgenic mice, comparison of the size of the first tumor on each animal at a fixed time after detection showed that the tumors in the double transgenic mice were significantly larger than those in the *MMTV-neu* transgenic mice (1.6 ± 0.2 versus 2.81 ± 0.3 cm³ in size, $P = 0.0004$; Figs. 2B and 4A). By histopathology, 57.6% of double transgenic tumors were poorly differentiated with a high histologic grade, <10% tubule formation, prominent nuclear pleomorphism, and evidence of high mitotic index (Fig. 4B). Similarly, in *MMTV-HER-2/neu* transgenic mice, 48.5% of the tumors were of high grade. Although there was no significant difference in the tumor grade distribution between *MMTV-HER-2/neu* and double transgenic tumors (Fig. 4B), the *MMTV-Hoxb7* × *MMTV-HER-2/neu* tumors showed a significantly higher mitotic index compared with the *MMTV-HER-2/neu* transgenic tumors





Figure 3. Effects of *Hoxb7* and *neu* overexpression on mammary gland development. *A*, inguinal mammary fat pads were excised from virgin mice at ages of 8 and 13 wk, pregnant mice at day 10, and involuting mice at day 3. The whole-mount staining analyses were performed as described previously (15). *Vir.*, virgin; *Preg.*, pregnant; *Invo.*, involution. *B*, analysis of branching of mammary gland whole mounts of 13-week-old virgin mice under the dissecting microscope. All side structures, including secondary/tertiary ductal branches, were counted in three fields per gland ($n = 4$ animals per group), and the average numbers are presented in the figure. *, $P < 0.05$. *C*, H&E-stained section of representative mammary glands at day 3 of involution. Scale bar, 50 μ m.

Figure 4. Overexpression of Hoxb7 promotes tumor growth. **A**, mammary tumor volume was significantly different ($P = 0.004$) in the *HER-2/neu* and *Hoxb7/HER-2/neu* transgenic mouse. The tumors were harvested at 10 wk after the first detection of a palpable mass. Tumor volume was calculated using the formula: $V \text{ (cm}^3\text{)} = [(\text{length}) / 2 \times (\text{width})^2]$. In each group, tumor volumes of only the earliest detectable tumors were compared. **B**, the grade distribution of tumors harvested from animals at 70 d after the initial tumor palpation. H&E-stained sections of tumors harvested from *HER-2/neu* and *Hoxb7/HER-2/neu* animals. Both tumors are poorly differentiated carcinomas. The nuclear size in the double transgenic tumors showed large variations. Tumors were graded according to the modified Elston and Ellis histologic grading system. Arrows indicate the mitotic cells. **C**, the number of mitotic cells counted on the H&E-stained tumor sections. Thirty-three randomly selected tumors from each group were analyzed. Mitotic cells were counted in 10 random high-power fields ($\times 400$) in each tumor sample. The Y axis represents the total mitotic cell number of 10 counted fields for each sample.



(35.2 ± 9.7 versus 24.2 ± 5.6 mitotic cells in 10 randomly selected fields, $P = 0.006$; Fig. 4C).

Furthermore, upon microscopic examination of multiple organs, we saw that 42.4% of *MMTV-HER-2/neu* transgenic mice harbored micrometastasis in the lung. In contrast, a comparatively higher number (66.7%) of double transgenic mice harbored micrometastasis in the lung (Fig. 5A and B). The average number of micrometastases per lung section in the double transgenic mice was more than twice that in the *HER-2/neu* transgenic mice (4.7 ± 1.1 versus 1.9 ± 0.5 lung foci per mouse; Fig. 5C). These data suggested that Hoxb7 promoted the formation of pulmonary metastatic lesions. No metastases were found in other organs in either *MMTV-HER-2/neu* or double transgenic mice.

Effects of Hoxb7 overexpression on angiogenesis, apoptosis, and proliferation in primary tumor cells. To gain an understanding of how Hoxb7 promoted tumor progression and metastasis, we examined the angiogenesis, cell death, and cell proliferation rate in the primary tumors. Overexpression of HOXB7 in breast cancer cell line SKBR3 cells was shown to promote angiogenesis and proliferation by up-regulating bFGF and a variety of proangiogenic factors (8, 10, 11). We examined the expression levels of bFGF in the primary tumors. The expression levels of bFGF were found to be augmented in double transgenic mice tumors compared with that in *MMTV-HER-2/neu* tumors (Supplementary Fig. S7). Angiogenesis were then assessed by anti-CD34 immunochemical staining of tumors from transgenic mice (Fig. 6A). Immunohistology showed that there was no significant difference in vascularization between *MMTV-HER-2/neu* and *MMTV-Hoxb7* \times *MMTV-HER-2/neu* mice tumors. Similarly, no significant difference in apoptotic death rate between these two types of tumors was found by immunochemical staining assay with an antibody against active caspase-3 (Fig. 6B). In contrast, we found that the tumors from the double transgenic mice had a much higher rate of proliferation compared with tumors arising in *MMTV-HER-2/neu* transgenic mice ($40.7 \pm 3.8\%$ versus $64.8 \pm 3.6\%$; $P < 0.001$; Fig. 6C). Therefore, promotion of cell proliferation was most likely a major mechanism of action of Hoxb7 in the late stages of tumor progression.

Discussion

In this study, we have established and characterized a mouse model to study the role of Hoxb7 in mammary tumorigenesis. To our knowledge, we have, for the first time, shown that a deregulated *HOX* gene plays a critical role in the formation and progression of solid tumors in a genetically engineered mouse model. An unpredicted and intriguing finding was that overexpression of Hoxb7 inhibited *MMTV-HER-2/neu*-induced tumor onset but, once tumors were formed, promoted tumor progression and metastasis. Our results further supported previous studies that overexpression of HOXB7 in human breast cancer cells increased cell proliferation rate and promoted tumor progression (11). In line with these findings, our clinical data also showed that HER-2-positive tumors with high levels of *HOXB7* showed a higher rate of metastasis and a poorer survival outcome.

One of the surprising findings in this study was that overexpression of Hoxb7 in the dual transgenic mice delayed *HER-2/neu*-induced tumor onset. At present, we can only speculate on the mechanisms underlying this phenomenon. Inhibition of tumorigenesis by overexpression of other oncogenes was reported recently in a few transgenic mouse models and cell culture systems (20–22, 25–27). There is growing recognition that overexpression of oncogenes can lead to premature growth arrest as a protection against tumor development (28). For example, overexpression of Ras or *HER-2/neu* in primary cultured cells induced premature senescence and differentiation (21, 22), whereas overexpression of oncogenic MYC triggered apoptosis (29). Only the cells which escape the oncogene-induced failsafe mechanism could eventually be transformed to form tumors. Recent studies have suggested that these escaping cells are most likely stem cells or precursor cells, which may truly be the targets of oncogenic transformation (20). In our double transgenic *MMTV-Hoxb7* \times *MMTV-HER-2/neu* mice, we speculate that overexpression of Hoxb7 in primary mammary epithelium triggered premature cellular differentiation, senescence, and/or apoptosis to eliminate large numbers of *MMTV-HER-2/neu* target cells and thereby protected the gland against

MMTV-neu-induced tumorigenesis. In line with this proposed differentiation/senescence function of *Hoxb7*, the *MMTV-Hoxb7* mice display an accelerated involution process, during which most of differentiated epithelial cells die through apoptosis but some of epithelial cells survive (30). This surviving epithelial cell population, named "parity-induced mammary epithelial cell population," serve as alveolar progenitors in subsequent pregnancies and are likely to be the cellular targets of transformation in *MMTV-HER-2/neu* transgenic mice (30, 31). Whether overexpression of *Hoxb7* specifically eliminated this cell population warrants further investigation. If so, it could provide a rational explanation of why *Hoxb7* expression inhibited *HER-2*-induced tumor onset.

Another possibility is that *Hoxb7* may directly or indirectly interfere with *HER-2/neu* signaling pathways. This hypothesis is supported by the fact that overexpression of *Hoxb7* rescued the *MMTV-HER-2/neu* caused defects in ductal elongation. It is known that overexpression of *neu* impedes ductal growth accompanying puberty (22, 23). This phenotype seems to be contradictory to the role of *neu* in promoting cellular proliferation during tumorigenesis. Recently, it was proposed that in the pubertal *MMTV* transgenic mice *neu* too has dual but opposing effects: it promotes ER α -dependent proliferation in the hyperplastic tissue but causes premature differentiation with a concomitant decrease in ER α -dependent

proliferation during normal ductal morphogenesis (22). *Hoxb7* is normally expressed in virgin mammary gland, but its function in ductal morphogenesis is as yet unknown (32). Rescue of the *MMTV-HER-2/neu* caused phenotype by *Hoxb7* during mammary gland development suggested that *Hoxb7* may partially block *HER-2/neu* signaling pathways at this stage. To compensate for this effect, only the cells with relatively high levels of *neu* expression escaped the suppressive restriction imposed by overexpression of *Hoxb7* and became transformed. Consistent with this notion, we observed that the expression levels of *neu* are slightly higher in double transgenic mouse tumors compared with *MMTV-HER-2/neu* tumors.

Upon detection, we observed that the double transgenic mouse tumors grew faster and were more aggressive. Examination of angiogenesis, cell proliferation, and apoptosis in these tumors revealed that the cell proliferation rate was significantly higher in double transgenic mice. However, overexpression of *Hoxb7* had no dramatic effects on angiogenesis and cell death. It has been reported that overexpression of *HOXB7* in human breast cancer cells promoted proliferation and angiogenesis in mouse xenografts by up-regulating bFGF and other proangiogenic factors (10, 11). In this study, as well, the expression levels of bFGF were relatively higher in double transgenic mice. However, contrary to previous reports, similar immunochemical staining did not reveal increased vascularization in *Hoxb7/HER-2/neu* tumors. These differences are most likely attributable to the different model systems used in these studies.

To our knowledge, this is the first report that dysregulation of *HOX* gene expression in a genetically engineered animal model dramatically modulated the process of tumor onset and progression. Despite numerous reports of misexpressed *HOX* genes in a variety of cancers, the loss or gain of *HOX* gene expression in genetically engineered animals is generally insufficient to cause tumor formation (6, 7). This has led to an argument whether dysregulated *HOX* gene expression is the cause or consequence of cancer (6). Our results clearly show that *HOX* genes played a critical role in the multistep process of tumor formation. In addition, we found that the function of *Hoxb7* in carcinogenesis seems to be dependent on the physiologic setting. Because factors governing these steps in neoplastic transformation *in vivo* are largely unknown, it is hard to predict whether other *HOX* genes will behave in a similar manner or whether *HOXB7* will play a dual role in carcinogenesis in other organs as well. Two opposing functions of *HOXB7* are supported by other studies in different cellular contexts. On the one hand, it has been reported that *HOXB7* exhibited transforming ability in NIH3T3 fibroblasts, a cell line prone to transformation (33). On the other hand, *HOXB7* overexpression in hematopoietic stem cells promoted myeloid differentiation (34) and, in multipotent mesenchymal cells, promoted differentiation to smooth muscle cells (35). In yet another study, *HOXB7* overexpression in immortalized normal ovarian surface epithelium cells failed to promote anchorage-independent growth, although increased proliferation and reduced contact inhibition were observed (9). These data suggest that elevated *HOXB7* expression levels may be associated with higher proliferative activity in tumors, rather than representing a step in the transformation process. These results are consistent with our data that overexpression of *Hoxb7* alone was insufficient to cause tumor formation in the mouse mammary gland. However, the possibility that *HOXB7* functions in cell transformation by acting in cooperation with other oncoproteins cannot be excluded.

In summary, overexpression of *Hoxb7* in the mammary gland of transgenic mice was insufficient to cause tumor formation but





Figure 5. *Hoxb7* transgene increases the frequency of pulmonary metastasis in the double transgenic mice. *A*, H&E-stained sections of lung from *HER-2/neu* and *Hoxb7/HER-2/neu* animals at 10 wk after the initial tumor palpation. Asterisks indicate lung metastasis. *B*, bar graph of number of animals harboring lung metastasis. *C*, comparison of the number of micrometastatic foci in the lung per animal in the two groups showed significant differences ($P = 0.03$ by the unpaired Student's *t* test).

Figure 6. Analysis of angiogenesis, apoptosis, and proliferation in *MMTV-neu* and *Hoxb7/neu* tumors. The immunochemical staining analysis was performed as described in Materials and Methods. **A**, angiogenesis was assessed by counting blood vessels after immunostaining with an anti-CD34 antibody. A total of 33 pairs of tumors were analyzed. The average blood vessel index was presented by counting the number of blood vessels at 200 \times magnification. The arrows indicate representative blood vessels in both *MMTV-neu* and *Hoxb7/neu* tumors. **B**, apoptotic rate was analyzed by immunostaining analysis with antibody against active caspase-3. The arrows indicate positively staining cells. One thousand cells per tumor were counted at 400 \times magnification, and the average percentage of positive cells was presented. **C**, proliferation rate was assessed by immunochemical staining analysis. Fifteen pairs of randomly selected *HER-2/neu* and *Hoxb7/HER-2/neu* transgenic tumors were immunohistochemically examined using the anti-Ki67 antibody. One thousand tumor cells per tumor were counted, and the percentage of Ki67-positive cells was calculated. Arrows indicate some of the positive cells.



dramatically affected *HER-2/neu*-induced tumorigenesis. It inhibited *HER-2/neu*-induced tumor onset while it promoted tumor growth and metastasis. Further studies aimed at understanding the mechanisms underlying this unusual phenotype have the potential to lead to identification of a novel target for breast cancer diagnosis and treatment.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

- Krumlauf R. Hox genes in vertebrate development. *Cell* 1994;78:191–201.
- Kongsuwan K, Webb E, Housiaux P, Adams JM. Expression of multiple homeobox genes within diverse mammalian haemopoietic lineages. *EMBO J* 1988;7: 2131–8.
- Cillo C. HOX genes in human cancers. *Invasion Metastasis* 1994;14:38–49.
- Cillo C, Cantile M, Faiella A, Boncinelli E. Homeobox genes in normal and malignant cells. *J Cell Physiol* 2001; 188:161–9.
- Cillo C, Faiella A, Cantile M, Boncinelli E. Homeobox genes and cancer. *Exp Cell Res* 1999;248:1–9.
- Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? *Nat Rev Cancer* 2002; 2:777–85.
- Chen H, Sukumar S. Role of homeobox genes in normal mammary gland development and breast tumorigenesis. *J Mammary Gland Biol Neoplasia* 2003; 8:159–75.
- Care A, Silvani A, Meccia E, et al. HOXB7 constitutively activates basic fibroblast growth factor in melanomas. *Mol Cell Biol* 1996;16:4842–51.
- Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. *Proc Natl Acad Sci U S A* 2001;98: 4060–5.
- Care A, Felicetti F, Meccia E, et al. HOXB7: a key factor for tumor-associated angiogenic switch. *Cancer Res* 2001;61:6532–9.
- Care A, Silvani A, Meccia E, Mattia G, Peschle C, Colombo MP. Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. *Oncogene* 1998;16:3285–9.
- Wu X, Chen H, Parker B, et al. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. *Cancer Res* 2006;66:9527–34.
- Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* 2005;365: 671–9.
- Gong Y, Yan K, Lin F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. *Lancet Oncol* 2007;8:203–11.
- Cardiff RD, Wagner U, Hennighausen L. Mammary cancer in humans and mice: a tutorial for comparative pathology. The CD-ROM. *J Mammary Gland Biol Neoplasia* 2000;5:243–4.

Acknowledgments

Received 7/31/2007; revised 2/21/2008; accepted 3/18/2008.

Grant support: Department of Defense DAMD-17-02-1-0426 (H. Chen), Department of Defense Center of Excellence W81XWH-04-1-0595, and National Cancer Institute/Specialized Programs of Research Excellence P50 CA88843 (S. Sukumar). This research was supported, in part, by Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research, and funded in part with federal funds from National Cancer Institute, NIH, under contract number NO1-CO-12400.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Todd Armstrong and Elizabeth Jaffee for graciously providing the *MMTV-HER-2/neu* mice.

16. Chen H, Rubin E, Zhang H, et al. Identification of transcriptional targets of HOXA5. *J Biol Chem* 2005;280:19373–80.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 1991;19:403–10.
18. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma *in situ* and invasive ductal carcinoma of the breast. *Oncogene* 2003;22:2021–33.
19. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci U S A* 1992;89:10578–82.
20. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence *in vivo* and its evasion during mammary tumorigenesis. *Nat Cell Biol* 2007;9:493–505.
21. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. *Cancer Res* 2005;65:840–9.
22. Shyamala G, Chou YC, Cardiff RD, Vargis E. Effect of c-neu/ErbB2 expression levels on estrogen receptor α -dependent proliferation in mammary epithelial cells: implications for breast cancer biology. *Cancer Res* 2006;66:10391–8.
23. Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. *Oncogene* 2000;19:5982–7.
24. Lazar H, Baltzer A, Gimmi C, Marti A, Jaggi R. Overexpression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis. *Int J Cancer* 2000;85:578–83.
25. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. *Proc Natl Acad Sci U S A* 2003;100:8430–5.
26. Kordon EC, McKnight RA, Jhappan C, Hennighausen L, Merlino G, Smith GH. Ectopic TGF β 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. *Dev Biol* 1995;168:47–61.
27. Braig M, Lee S, Lodenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature* 2005;436:660–5.
28. Sharpless NE, DePinho RA. Cancer: crime and punishment. *Nature* 2005;436:636–7.
29. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell* 2002;109:321–34.
30. Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. *Development* 2002;129:1377–86.
31. Henry MD, Triplett AA, Oh KB, Smith GH, Wagner KU. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. *Oncogene* 2004;23:6980–5.
32. Srebrow A, Friedmann Y, Ravanpay A, Daniel CW, Bissell MJ. Expression of Hoxa-1 and Hoxb-7 is regulated by extracellular matrix-dependent signals in mammary epithelial cells. *J Cell Biochem* 1998;69:377–91.
33. Maulbecker CC, Gruss P. The oncogenic potential of deregulated homeobox genes. *Cell Growth Differ* 1993;4:431–41.
34. Care A, Valtieri M, Mattia G, et al. Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. *Oncogene* 1999;18:1993–2001.
35. Bostrom K, Tintut Y, Kao SC, Stanford WP, Demer LL. HOXB7 overexpression promotes differentiation of C3H10T1/2 cells to smooth muscle cells. *J Cell Biochem* 2000;78:210–21.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Hoxb7 Inhibits Transgenic HER-2/neu–Induced Mouse Mammary Tumor Onset but Promotes Progression and Lung Metastasis

Hexin Chen, Ji Shin Lee, Xiaohui Liang, et al.

Cancer Res 2008;68:3637-3644. Published OnlineFirst May 7, 2008.

Updated version

Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-07-2926](https://doi.org/10.1158/0008-5472.CAN-07-2926)

Supplementary Material

Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2008/05/09/68.10.3637.DC1>

Cited articles

This article cites 35 articles, 10 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/10/3637.full#ref-list-1>

Citing articles

This article has been cited by 8 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/68/10/3637.full#related-urls>

E-mail alerts

[Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.